Similar articles

• Factors influencing fluoroquinolone resistance.

  Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Sahm DF, et al. Emerg Infect Dis. 2003 Dec;9(12):1651-4. doi: 10.3201/eid0912.030168. Emerg Infect Dis. 2003. PMID: 14725310 Free PMC article. No abstract available.
• In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.

  Johnson AP, Speller DC, Warner M, Domingue G. Johnson AP, et al. J Antimicrob Chemother. 1996 Nov;38(5):907-8. doi: 10.1093/jac/38.5.907. J Antimicrob Chemother. 1996. PMID: 8961064 No abstract available.
• A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.

  Wise R, Andrews JM. Wise R, et al. J Chemother. 1998 Aug;10(4):276-9. doi: 10.1179/joc.1998.10.4.276. J Chemother. 1998. PMID: 9720464
• Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections.

  Marchetti F, Viale P. Marchetti F, et al. J Chemother. 2003 Aug;15(4):315-22. doi: 10.1179/joc.2003.15.4.315. J Chemother. 2003. PMID: 12962358 Review.
• [New microbiological data on the susceptibility of Pneumococci to levofloxacin].

  Soussy CJ. Soussy CJ. Presse Med. 2002 Jun 15;31(21 Pt 2):S5-10. Presse Med. 2002. PMID: 12148387 Review. French.